One of the most underappreciated trade-offs of GLP-1 receptor agonist therapy is that a substantial portion of the weight lost is lean tissue, not fat. For the millions now using semaglutide long-term, this muscle attrition could quietly erode the very metabolic and functional health the drug is meant to protect — making any strategy that preserves lean mass without blunting fat loss clinically significant.
Using an obese, glucose-intolerant mouse model treated over three weeks, researchers found that semaglutide monotherapy reduced lean mass, measurably weakened grip strength and endurance, and shifted skeletal muscle gene expression toward atrophy — suppressing mitochondrial biogenesis markers while upregulating proteolytic pathways. When a β-hydroxybutyrate-producing ketone ester was co-administered orally alongside semaglutide, lean mass and physical performance were largely preserved, and the adverse shifts in mitochondrial and atrophy-related gene expression were substantially reversed — all without diminishing fat loss.
This finding matters because it proposes a mechanistic explanation: GLP-1RA-driven caloric restriction may impair ketone metabolism and mitochondrial function in skeletal muscle, and exogenous ketone supplementation can compensate for that deficit. The β-hydroxybutyrate signal appears to act as a protective metabolic substrate or signaling molecule within muscle tissue under energy-restricted conditions.
Several important caveats apply. This is a preclinical, rodent-only study, and the translation to humans is not established. Mouse skeletal muscle physiology and the three-week timeline do not capture the chronicity of human GLP-1RA use, which often extends to years. The dose of ketone ester used and its human-equivalent tolerability remain open questions. Additionally, while gene expression changes are informative, downstream protein-level and functional human outcomes are needed before clinical conclusions can be drawn. Within the broader sarcopenia-prevention landscape — where resistance training is still the best-validated countermeasure — ketone supplementation as an adjunct represents an incremental but genuinely novel hypothesis worth pursuing in human trials.